Glaucoma Debate Club 2022: Cases in Sustained IOP Control (CME Symposium)
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Review safety and efficacy data for approved and emerging sustained-release drug delivery devices for glaucoma
- Identify patients with glaucoma who are most likely to benefit from sustained-release drug delivery treatment
- Choose appropriate MIGS procedures for a variety of patient scenario
Iqbal Ike K. Ahmed, MD, FRCSC (Co-Chair)
Department of Ophthalmology and Visual Sciences
University of Utah
Salt Lake City, Utah
Director, Alan S. Crandall Center for Glaucoma Innovation
John A. Moran Eye Center
Director, Glaucoma & Advanced Anterior Segment Surgery (GAASS) Fellowship
Research Director, Kensington Eye Institute
University of Toronto
Division Head, Ophthalmology
Trillium Health Partners
Chief Innovation Officer
Prism Eye Institute
Thomas W. Samuelson, MD (Co-Chair)
Founding Partner and Attending Surgeon
Glaucoma and Anterior Segment Surgery
Minnesota Eye Consultants
University of Minnesota
Marlene R. Moster, MD
Professor of Ophthalmology
Thomas Jefferson University School of Medicine
Attending Surgeon, Glaucoma Service
Wills Eye Institute
Arsham Sheybani, MD
Assistant Professor of Ophthalmology
Fellowship Director, Glaucoma and Anterior Segment Surgery
Residency Program Director, Ophthalmology
Washington University School of Medicine
St Louis, Missouri
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Iqbal Ike K. Ahmed, MD, is a consultant for Aequus BioPharma, Inc, Aerie Pharmaceuticals, Inc, Akorn, Inc, Alcon, Allergan, Aquea Health, Inc, ArcScan, Inc, Avisi, Bausch & Lomb Incorporated, Beaver-Visitec International, Beyeonics Surgical Ltd, Bionode, Carl Zeiss Meditec, Inc, CorNeat Vision Ltd, Elios Vision, ElutiMed, Equinox, Genentech, Inc, Glaukos Corporation, Heine, Heru, Iantrek, Injectsense, Inc, IRIDEX Corporation, iCare, iSTAR, Ivantis Inc, Johnson & Johnson Vision Care, Inc, LayerBio, Inc, MicroOptx, MicroSurgical Technology, Myra Vision, New World Medical, Inc, Ocular Instruments, Ocular Therapeutix, Inc, Omega Ophthalmics, Polyactiva Pty Ltd, Radiance Therapeutics, Inc, Ripple Therapeutics, Sanoculis Ltd, Santen Inc, Shifamed, LLC, Sight Sciences, Smartlens, Inc, Strõma Medical Corporation, Thea Pharmaceuticals Limited, Vialase, Inc, Vizzario, and W. L. Gore & Associates, Inc; is on the speakers bureau for Alcon, Allergan, Carl Zeiss Meditec, Inc, Heine, Johnson & Johnson Vision Care, Inc, and MicroSurgical Technology; and is a contracted researcher for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bionode, Glaukos Corporation, iCare, Ivantis Inc, Johnson & Johnson Vision Care, Inc, New World Medical, Inc, and Santen Inc.
Marlene R. Moster, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, and Qura; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Alcon, Allergan, and Bausch & Lomb Incorporated; is a contracted researcher for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Glaukos Corporation, InnFocus, Inc, and New World Medical, Inc; and has individual stocks or stock options in Qura.
Thomas W. Samuelson, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Belkin Vision, ELT Sight, Equinox, Glaukos Corporation, Imprimis Pharmaceuticals, Inc, Ivantis Inc, Johnson & Johnson Vision Care, Inc, MicroOptx, New World Medical, Inc, Ocuphire Pharma, Polyactiva Pty Ltd, Ripple Therapeutics, Santen Inc, Sight Sciences, TearClear, Valeant, ViaLase, Inc, and Zeiss; and has individual stocks or stock options in Belkin Vision, Equinox, Ivantis Inc, Ocuphire Pharma, Sight Sciences, TearClear, and ViaLase, Inc.
Arsham Sheybani, MD, is a consultant for AbbVie Inc, Alcon, Glaukos Corporation, Ivantis Inc, and Santen Inc.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from AbbVie Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or AbbVie Inc.
©2022 MedEdicus LLC. 265
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation